Why do BCL-2 inhibitors work and where should we use them in the clinic?

DSpace/Manakin Repository

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Citable link to this page

 

 
Title: Why do BCL-2 inhibitors work and where should we use them in the clinic?
Author: Montero, Joan; Letai, Antony

Note: Order does not necessarily reflect citation order of authors.

Citation: Montero, Joan, and Antony Letai. 2018. “Why do BCL-2 inhibitors work and where should we use them in the clinic?” Cell Death and Differentiation 25 (1): 56-64. doi:10.1038/cdd.2017.183. http://dx.doi.org/10.1038/cdd.2017.183.
Full Text & Related Files:
Abstract: Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-family interactions makes it challenging to predict cell fate via standard molecular biology techniques. We discuss BCL-2 family regulation and how to determine cells’ readiness for apoptosis and anti-apoptotic dependence. Cancer cells often adopt anti-apoptotic defense mechanisms in response to oncogenic stress or anti-cancer therapy. However, by determining their anti-apoptotic addiction, we can use novel BH3 mimetics to overwhelm this apoptotic blockade. We outline the development and uses of these unique anti-apoptotic inhibitors and how to possibly combine them with other anti-cancer agents using dynamic BH3 profiling (DBP) to improve personalized cancer treatment.
Published Version: doi:10.1038/cdd.2017.183
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729538/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34868855
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters